ストックスクリーナーアプリを入手
49.89
1.93%
-0.98
アフターアワーズ：
49.91
0.02
+0.04%
前日終値:
$50.87
開ける：
$49.7
24時間の取引高:
2.28M
Relative Volume:
0.60
時価総額：
$99.92B
収益：
$43.93B
当期純損益:
$8.53B
株価収益率:
13.05
EPS:
3.824
ネットキャッシュフロー:
$5.74B
1週間 パフォーマンス:
-1.83%
1か月 パフォーマンス:
-3.18%
6か月 パフォーマンス:
-12.21%
1年 パフォーマンス:
+25.95%
1日の値動き範囲:
$49.66
$50.06
1週間の範囲:
$49.66
$51.52
52週間の値動き範囲:
$39.29
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
49.89 | 104.07B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-06 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-11-25 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-06-03 | ダウングレード | Berenberg | Buy → Hold |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-11-12 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-07-08 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-30 | 開始されました | Goldman | Neutral |
| 2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2024-01-03 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 再開されました | Goldman | Buy |
| 2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-11 | ダウングレード | UBS | Neutral → Sell |
| 2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 再開されました | Citigroup | Neutral |
| 2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Hold |
| 2020-11-02 | アップグレード | Liberum | Hold → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
| 2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 開始されました | SVB Leerink | Outperform |
| 2019-11-21 | アップグレード | UBS | Neutral → Buy |
| 2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 再開されました | Citigroup | Neutral |
| 2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
| 2019-08-13 | 再開されました | JP Morgan | Neutral |
| 2019-06-17 | 再開されました | Morgan Stanley | Underweight |
| 2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
| 2019-02-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-08-30 | ダウングレード | Liberum | Buy → Hold |
| 2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - AD HOC NEWS
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - Sahm
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - AD HOC NEWS
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
GSK Stock Quote Price and Forecast - CNN
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK reports Jemperli rectal cancer trial results - grafa.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
Price to earnings forward of GSK plc Sponsored ADR – MUN:GS70 - TradingView
GSKGSK Plc ADR Latest SEC Filings - Finviz
GS70 Forecast — Price Target — Prediction for 2027 - TradingView
Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96% - Stock Titan
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
Price to earnings forward of GSK plc Sponsored ADR – LS:A3DMHS - TradingView
A3DMHS Forecast — Price Target — Prediction for 2027 - TradingView
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK (GSK) reports major holder crossing 5% voting rights threshold - Stock Titan
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Actuals & Estimates (BCBA:GSKC) - TradingView
Why GSK's Shingrix is reshaping the shingles vaccine market - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Sahm
Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
GSK secures dual US and EU orphan drug status for momelotinib in VEXAS - grafa.com
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
Gsk Plc Adr (GSK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| GSK plc | 10% Owner |
Dec 11 '25 |
Buy |
19.00 |
1,470,000 |
27,930,000 |
18,245,691 |
1.25%
大文字化:
|
ボリューム (24 時間):